Get the Stockscreener App
0.4665
1.70%
0.0078
After Hours:
.45
-0.0165
-3.54%
Verrica Pharmaceuticals Inc stock is traded at $0.4665, with a volume of 183.48K.
It is up +1.70% in the last 24 hours and down -10.65% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.4587
Open:
$0.4576
24h Volume:
183.48K
Relative Volume:
0.49
Market Cap:
$45.02M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-0.3173
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-4.89%
1M Performance:
-10.65%
6M Performance:
-68.90%
1Y Performance:
-93.13%
1-Day Range:
$0.449
$0.4945
1-Week Range:
$0.4395
$0.4999
52-Week Range:
$0.3816
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.4665 | 45.02M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MyChesCo
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns "Neutral" Rating from HC Wainwright - MarketBeat
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MSN
Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
HC Wainwright Analysts Decrease Earnings Estimates for VRCA - Defense World
What is HC Wainwright’s Forecast for VRCA FY2028 Earnings? - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Receives “Neutral” Rating from HC Wainwright - Defense World
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN
H.C. Wainwright maintains Neutral on Verrica stock after Q1 update By Investing.com - Investing.com Canada
Verrica Pharmaceuticals at Needham Conference: Strategic Restructuring and Growth By Investing.com - Investing.com Canada
In face of U.S. stock market selloff, shares of West Chester firm are on the rise - The Business Journals
Verrica Pharmaceuticals Reports Strong Demand-Led Growth In Ycanth® In Q1 2025 - marketscreener.com
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 - The Manila Times
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in - GlobeNewswire
Record-Breaking Quarter: YCANTH Crosses 10K Units Milestone with 17% Growth - Stock Titan
Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now - MSN
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - The Manila Times
Verrica Pharmaceuticals appoints new board member - Investing.com Australia
Verrica Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MyChesCo
Verrica Pharmaceuticals expands board with new director By Investing.com - Investing.com Canada
Verrica Pharmaceuticals Appoints Dr. Corcoran as Director - TipRanks
Verrica Pharmaceuticals expands board with new director - Investing.com
Strategic Move: Verrica Adds Formation Bio CDO to Board Amid YCANTH Success - Stock Titan
Verrica Pharmaceuticals to Present at Needham Healthcare Conference - MSN
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Harmony, Lungpacer, Verrica and Arbutus make C-suite hires - The Business Journals
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com
Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan
VRCA stock plunges to 52-week low, touches $0.5 - Investing.com
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):